Bicycle Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BCYC and other ETFs, options, and stocks.

About BCYC

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. 

CEO
Kevin Lee
CEOKevin Lee
Employees
288
Employees288
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
2009
Founded2009
Employees
288
Employees288

BCYC Key Statistics

Market cap
368.34M
Market cap368.34M
Price-Earnings ratio
-1.68
Price-Earnings ratio-1.68
Dividend yield
Dividend yield
Average volume
409.81K
Average volume409.81K
High today
$5.32
High today$5.32
Low today
$5.17
Low today$5.17
Open price
$5.28
Open price$5.28
Volume
90.11K
Volume90.11K
52 Week high
$9.55
52 Week high$9.55
52 Week low
$4.24
52 Week low$4.24

BCYC News

TipRanks 4h
Bicycle Therapeutics Advances EphA2 Oncology Pipeline With New Data

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Analyst ratings

67%

of 12 ratings
Buy
66.7%
Hold
33.3%
Sell
0%

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.